Tyler Menichiello
Tyler Menichiello is chief editor of Bioprocess Online, where he interviews biopharma executives and subject matter experts about the industry’s most pressing challenges. He aims to deliver actionable insights for biologics developers and manufacturers. Previously, he spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, working on clinical trials for hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can connect with Tyler on LinkedIn.
ARTICLES BY TYLER MENICHIELLO
-
![Crowley Pic (1)]( "BIO 2026: Crowley On Competing With China And Modernizing The FDA")
BIO 2026: Crowley On Competing With China And Modernizing The FDA7/8/2026Exclusive coverage from John Crowley's press conference at the 2026 BIO International Convention in San Diego.
-
![Oil, water, and blue pigment particles-GettyImages-1153909630]( "Essential CMC Elements For A Therapeutic Secretome")
Essential CMC Elements For A Therapeutic Secretome6/30/2026Noveome Biotherapeutics's Larry Brown, Sc.D., explains the regulatory and CMC challenges behind the company's novel secretome therapy, ST266.
-
![26_06_betterbio_edit_round__midyear_450x300]( "Midyear Pulse Check: What's Shaping Biopharma In 2026?")
Midyear Pulse Check: What's Shaping Biopharma In 2026?6/16/2026This article summarizes the major developments and industry pressures highlighted by Life Science Connect editors in the "Better Biopharma" midyear editorial roundtable.
-
![Path to success-GettyImages-2208609141]( "Reflecting On Continued Turbulence At The FDA")
Reflecting On Continued Turbulence At The FDA5/26/2026Bioprocess Online's Editorial Advisory Board responds to former FDA commissioner Marty Makary’s resignation amid a prolonged period of instability at the agency.
-
![Business solutions, problems found, problem solving-GettyImages-2221582544]( "Insufficient Vendor Data Is Hamstringing Single-Use Adoption")
Insufficient Vendor Data Is Hamstringing Single-Use Adoption5/20/2026Audience polls and expert insights reveal insufficient vendor data as the main bottleneck stalling advanced single-use technology adoption. Explore that and other key takeaways in this recap of the Bioprocess Online Live event on "Closing The Adoption Gap For Advanced Single-Use Materials."
-
![2026_Rau Interview_NextGen Biomed]( "On The Ground At NextGen Biomed 2026")
On The Ground At NextGen Biomed 20264/29/2026Bioprocess Online caught up with Tiffany D. Rau, Ph.D., CMC consultant and adjunct professor of biochemistry and cell biology at the University College Cork in Ireland, at Oxford Global's 2026 NextGen Biomed conference.
-
![Rowers on an arrow-GettyImages-2230670817]( "Integrate Upstream/Downstream To Reduce Development Risks And Costs")
Integrate Upstream/Downstream To Reduce Development Risks And Costs4/8/2026Coordinating unit operations can help reduce costs and mitigate challenges in process development. Check out these key takeaways from the Bioprocess Online Live event “Optimizing Process Development Through Upstream and Downstream Integration.”
-
![Futuristic central processor unit-GettyImages-1464561980]( "Taking The First Steps Towards Digitalizing Biopharma Development")
Taking The First Steps Towards Digitalizing Biopharma Development1/28/2026AbbVie's head of biologics purification development and digitization teams, Moiz Diwan, Ph.D., and independent technology consultant Kat Kozyrytska share their thoughts on AI and smart technology adoption in this recap of the Bioprocess Online Live event, “How Digital Tools Are Accelerating Biopharma Development.”
-
![year 2025-GettyImages-2187124625]( "Bioprocess Online's 2025 Editorial Reflections")
Bioprocess Online's 2025 Editorial Reflections12/23/2025Bioprocess Online's chief editor, Tyler Menichiello, reflects on the year and provides a preview of what to expect in 2026.
-
![Fda Headquarters-GettyImages-2211199138]( "FDA Releases Draft Guidance To Accelerate Biosimilar Development")
FDA Releases Draft Guidance To Accelerate Biosimilar Development10/31/2025New FDA draft guidance aims to reduce the timeline and cost of developing biosimilars.
